StockData

Yarrow Bioscience, Inc. (YARW) shareholders

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30102% above fair value
$14.21+0.28 (+2.01%)

Close on Nov 17, 2026Market cap $37.94MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
11.6%
0M of 3M shares
Institutional holders
45
6 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Daniel Mack
Joint filing with Nantahala Capital Management, LLC (6.00%), Wilmot B. Harkey (6.00%)
2,000,0006.00%13G (passive)Mar 31, 2026
Eventide Asset Management, LLC
Joint filing with Finny Kuruvilla, M.D. Ph. D. (9.99%), Robin C. John (9.99%)
1,849,5979.99%13G (passive) amendmentJun 30, 2025
Bellevue Asset Management AG
Joint filing with Bellevue Group AG (10.60%)
1,000,00010.60%13G (passive)Sep 10, 2026
Raymond Debbane
Joint filing with Invus Public Equities, L.P. (6.30%), Invus Public Equities Advisors, LLC (6.30%) and 2 more
675,0007.20%13G (passive)Sep 11, 2026
Logos Global Management GP LLC
Joint filing with Logos Global Management LP (10.70%), Arsani William (10.70%) and 2 more
286,30810.70%13G (passive) amendmentJul 31, 2026
venBio Global Strategic Fund V, L.P.
Joint filing with venBio Global Strategic GP V, LLC (9.99%)
279,3409.99%13G (passive)Jul 27, 2026
Logos Global Management LP
Joint filing with Logos Global Management GP LLC (9.90%), Arsani William (9.90%) and 5 more
276,7049.90%13G (passive)Jul 27, 2026
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (9.99%), Joseph Edelman (9.99%)
266,7569.99%13G (passive)Jul 27, 2026
JANUS HENDERSON GROUP Ltd.266,7129.99%13G (passive)Jul 31, 2026
RTW Fund Group GP, LLC
Joint filing with Roderick Wong (9.99%)
266,3079.99%13G (passive)Jul 27, 2026
Orbimed Advisors LLC
Joint filing with OrbiMed Capital GP X LLC (8.73%), OrbiMed Capital GP X, LP (8.73%)
266,3069.97%13D (active)Jul 27, 2026
Len Blavatnik
Joint filing with AI Biotechnology LLC (6.02%), Access Industries Holdings LLC (6.02%) and 1 more
178,1806.02%13D (active) amendmentJul 27, 2026
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (8.80%)
59,0008.80%13G (passive)Jun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of YARWValueChange% of portfolio
Nantahala Capital Management, LLC80,0003.00%$2.60M+40,0000.04%
ADAR1 Capital Management, LLC59,0002.21%$1.92M+37,7220.09%
Lynx1 Capital Management LP32,5741.22%$1.06M–0.12%
Shay Capital LLC29,1331.09%$947.84K−3,0720.06%
T3 Companies, LLC18,9000.71%$614.91K–0.66%
Braidwell LP18,3220.69%$596.09K–0.02%
KVP Capital Advisors, LP10,0110.37%$325.71K–0.24%
Citadel Advisors LLC9,3690.35%$304.83K−9200.00%
Two Sigma Investments, LP8,7760.33%$285.54K+2480.00%
Acadian Asset Management LLC7,6360.29%$248.00K–0.00%
Ikarian Capital, LLC5,2980.20%$172.38K–0.02%
Vanguard Capital Management LLC5,2910.20%$172.23K–0.00%
Geode Capital Management, LLC5,1640.19%$168.02K−1,2900.00%
Vanguard Fiduciary Trust Co3,6690.14%$119.42K–0.00%
Susquehanna International Group, Llp2,3790.09%$77.41K+1,2230.00%
Rangeley Capital, LLC2,2610.08%$73.57K−1000.07%
XTX Topco Ltd1,5740.06%$51.22K−1,5940.00%
Gsa Capital Partners Llp1,4310.05%$47.00KNew0.00%
Superstring Capital Management LP1,2250.05%$39.87KNew0.03%
UBS Group AG1,1720.04%$38.15K−2,4240.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026450M11.6%6 / 79 / 40M0M
Q1 2026440M10.8%8 / 114 / 40M0M
Q4 2025430M6.9%13 / 108 / 30M0M
Q3 2025330M2.9%7 / 86 / 180M0M
Q2 2025440M6.0%14 / 912 / 70M0M
Q1 2025370M5.3%7 / 147 / 40M0M
Q4 2024340M5.3%9 / 98 / 60M0M
Q3 2024320M5.7%3 / 412 / 00M0M
Q2 2024300M6.0%2 / 129 / 20M0M
Q1 2024300M5.8%4 / 76 / 60M0M
Q4 2023320M5.9%13 / 103 / 10M0M
Q3 2023200M0.3%3 / 46 / 10M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Rebecca FreyChief Executive Officer, Director––Oct 30, 2026
David DomzalskiPRESIDENT AND CEO, Director347,17413.00%Jul 24, 2026
Tyler ZerondaChief Financial Officer74,9182.81%Oct 30, 2026
Rachael AlfordChief Operating Officer––Oct 30, 2026
Steven RyderChief Medical Officer––Oct 30, 2026
Lori PaytonChief Development Officer––Oct 30, 2026
Mutya HarschCHIEF LEGAL OFFICER AND GC95,9183.59%Jul 24, 2026
Iain StuartCHIEF SCIENTIFIC OFFICER95,9443.59%Jul 24, 2026
Capital GP X. LLC OrbiMedDirector––Jul 29, 2026
Genesis GP LLC OrbiMedDirector––Jul 29, 2026
Steven L. HoerterDirector––Jul 29, 2026
Advisors Llc OrbimedDirector233,0198.73%Jul 29, 2026
Mona AshiyaDirector33,2871.25%Jul 29, 2026
Peter B. SilvermanDirector––Jul 29, 2026
William Richard WhiteDirector––Jul 29, 2026
Sven Ante LundbergDirector––Jul 29, 2026
Elisabeth Sandoval LittleDirector––Dec 15, 2025
Steven L. BastaDirector853,94231.99%Dec 15, 2025
Patrick G. LeporeDirector51,4721.93%Dec 15, 2025
Sharon BarbariDirector75,0002.81%Dec 15, 2025
Christine BorowskiDirector––Dec 13, 2024
Anthony D. BrunoDirector120,1234.50%Dec 13, 2024
RTW Fund Group GP, LLC10% owner399,59714.97%Jul 30, 2026
Roderick Wong10% owner266,3079.97%Jul 30, 2026
Life Sciences Master Fund Ltd Perceptive10% owner5,435,057203.58%Jul 29, 2026
Advisors Llc Perceptive10% owner266,3099.98%Jul 29, 2026
Joseph Edelman10% owner4,935,057184.85%Jul 29, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Roderick Wong
10% owner
Jul 29, 2026Other−133,290––266,307
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Jul 23, 2026Tax withholding−22,516$0.90$20.26K95,918
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Jul 23, 2026Tax withholding−15,405$0.90$13.86K95,944
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Jul 23, 2026Tax withholding−22,516$0.90$20.26K74,918
David Domzalski
PRESIDENT AND CEO, Director
Jul 23, 2026Tax withholding−79,391$0.90$71.45K347,174
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Jun 30, 2026Tax withholding−3,464$0.65$2.25K97,434
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Jun 30, 2026Tax withholding−2,370$0.65$1.54K111,349
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Jun 30, 2026Tax withholding−3,464$0.65$2.25K118,434
David Domzalski
PRESIDENT AND CEO, Director
Jun 30, 2026Tax withholding−12,214$0.65$7.94K426,565
David Domzalski
PRESIDENT AND CEO, Director
May 29, 2026Award+30,791$0.31$9.55K438,779
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Mar 31, 2026Tax withholding−4,007$0.60$2.40K121,898
David Domzalski
PRESIDENT AND CEO, Director
Mar 31, 2026Tax withholding−14,232$0.60$8.54K401,976
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Mar 31, 2026Tax withholding−4,007$0.60$2.40K99,788
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Mar 31, 2026Tax withholding−2,876$0.60$1.73K112,363
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Dec 31, 2025Tax withholding−3,579$0.58$2.08K125,905
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Dec 31, 2025Tax withholding−2,448$0.58$1.42K115,239
David Domzalski
PRESIDENT AND CEO, Director
Dec 31, 2025Tax withholding−12,684$0.58$7.36K416,208
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Dec 31, 2025Tax withholding−7,858$0.58$4.56K103,795
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Sep 30, 2025Tax withholding−2,453$0.34$834117,687
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Sep 30, 2025Tax withholding−3,581$0.34$1.22K129,484
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Sep 30, 2025Tax withholding−3,420$0.34$1.16K111,653
David Domzalski
PRESIDENT AND CEO, Director
Sep 30, 2025Tax withholding−12,676$0.34$4.31K428,892
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Jun 30, 2025Tax withholding−3,420$1.65$5.64K115,073
David Domzalski
PRESIDENT AND CEO, Director
Jun 30, 2025Tax withholding−12,676$1.65$20.92K441,568
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Jun 30, 2025Tax withholding−2,453$1.65$4.05K120,140
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Jun 30, 2025Tax withholding−3,581$1.65$5.91K133,065
David Domzalski
PRESIDENT AND CEO, Director
Jun 2, 2025Award+8,681$0.81$7.03K454,244
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Jun 2, 2025Award+1,145$0.81$927136,646
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Mar 31, 2025Tax withholding−8,828$1.58$13.95K135,501
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Mar 31, 2025Tax withholding−8,399$1.58$13.27K118,493
David Domzalski
PRESIDENT AND CEO, Director
Mar 31, 2025Tax withholding−30,498$1.58$48.19K445,563
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Mar 31, 2025Tax withholding−6,044$1.58$9.55K122,593
Patrick G. Lepore
Director
Jan 15, 2025Buy+15,000$2.92$43.80K51,472
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Dec 31, 2024Tax withholding−4,697$3.35$15.73K144,329
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Dec 31, 2024Tax withholding−4,675$3.35$15.66K126,892
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Dec 31, 2024Tax withholding−4,857$3.35$16.27K128,637
David Domzalski
PRESIDENT AND CEO, Director
Dec 31, 2024Tax withholding−24,536$3.35$82.20K476,061
David Domzalski
PRESIDENT AND CEO, Director
Nov 30, 2024Award+3,901$2.10$8.19K500,597
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Sep 30, 2024Tax withholding−84$1.88$158131,567
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Sep 30, 2024Tax withholding−109$1.88$205133,494
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Sep 30, 2024Tax withholding−105$1.88$197149,026
David Domzalski
PRESIDENT AND CEO, Director
Sep 30, 2024Tax withholding−685$1.88$1.29K496,696
David Domzalski
PRESIDENT AND CEO, Director
Jul 1, 2024Tax withholding−935$1.92$1.80K497,654
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Jul 1, 2024Tax withholding−138$1.92$265133,603
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Jul 1, 2024Tax withholding−143$1.92$275149,131
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Jul 1, 2024Tax withholding−92$1.92$177131,651
David Domzalski
PRESIDENT AND CEO, Director
May 31, 2024Award+4,429$2.16$9.57K498,589
David Domzalski
PRESIDENT AND CEO, Director
Apr 1, 2024Tax withholding−1,004$3.08$3.09K494,160
Mutya Harsch
CHIEF LEGAL OFFICER AND GC
Apr 1, 2024Tax withholding−161$3.08$496149,274
Iain Stuart
CHIEF SCIENTIFIC OFFICER
Apr 1, 2024Tax withholding−157$3.08$484133,741
Tyler Zeronda
CHIEF FINANCIAL OFFICER
Apr 1, 2024Tax withholding−94$3.08$290131,743
David Domzalski
President and CEO, Director
Jan 2, 2024Tax withholding−1,004$2.28$2.29K495,164
Tyler Zeronda
Chief Financial Officer
Jan 2, 2024Tax withholding−93$2.28$212131,837
Iain Stuart
Chief Scientific Officer
Jan 2, 2024Tax withholding−157$2.28$358133,898
Mutya Harsch
Chief Legal Officer and GC
Jan 2, 2024Tax withholding−161$2.28$367149,435
David Domzalski
President and CEO, Director
Jan 1, 2024Award+225,000––496,168
Tyler Zeronda
Chief Financial Officer
Jan 1, 2024Award+62,500––131,930
Iain Stuart
Chief Scientific Officer
Jan 1, 2024Award+62,500––134,055
Mutya Harsch
Chief Legal Officer and GC
Jan 1, 2024Award+62,500––149,596
Tyler Zeronda
Chief Financial Officer
Dec 13, 2023Award+62,500––69,430

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
29.72%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+7.5%
From 0M shares
Short volume, 20 days
36.8%
Of volume reported to FINRA

Shares sold short, last 4 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Yarrow Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,180 shares on Oct 13, 2026 over the last 90 days.

See a number that looks wrong?